Future Destinations
Research type
Research Study
Full title
Journeys towards citizenship: How people cured of Hepatitis C (HCV) using Direct-Acting Antiviral (DAA) drugs progress in a new HCV-free world.
IRAS ID
269190
Contact name
John F Dillon
Contact email
Sponsor organisation
University of Dundee
Duration of Study in the UK
2 years, 6 months, 0 days
Research summary
Hepatitis C is a liver disease caused by the hepatitis C virus (HCV), if left untreated it can lead to chronic liver disease, cirrhosis and cancer. HCV is a blood borne virus, the key risk group for HCV infection are those who currently inject drugs, or have done in the past.
For many years the treatment of chronic HCV infection was based on therapies that had significant side effects, long treatment period and were between 50-70% effective, this impacted on patient acceptability and compliance. However, for those completing the treatment and undergoing this “personal trial” literature describes the transformative experience of HCV cure and how people took steps towards a “normal life” moving beyond substance use.
Recent advances in Direct-Acting Antiviral (DAA) medicines available to cure HCV have transformed treatment with shorter treatment periods, few side effects, ease of administration and improved efficacy. However, there is a potential paradox, in that the DAA-based regimes provide a reliable cure, for a large majority of patients, with a relatively small treatment burden, but may not be a “personal trial” and may have a lesser impact on rehabilitation and recovery from substance use.
The success of attempts of the group cured of HCV with DAAs, to progress down a recovery pathway and to resume activities thought of as being part of normal citizenship, are therefore unclear.
This study will examine the types of activities that people cured of HCV undertake and the success of their recovery pathway, post-treatment with DAAs over a two year follow-up period.REC name
East of Scotland Research Ethics Service REC 1
REC reference
19/ES/0129
Date of REC Opinion
14 Nov 2019
REC opinion
Further Information Favourable Opinion